Repositioning Candidate Details
| Candidate ID: | R1293 |
| Source ID: | DB09304 |
| Source Type: | experimental |
| Compound Type: | small molecule |
| Compound Name: | Setiptiline |
| Synonyms: | Setiptiline |
| Molecular Formula: | C19H19N |
| SMILES: | CN1CCC2=C(C1)C1=CC=CC=C1CC1=CC=CC=C21 |
| Structure: |
|
| DrugBank Description: | Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989. |
| CAS Number: | 57262-94-9 |
| Molecular Weight: | 261.368 |
| DrugBank Indication: | For the treatment of depression . |
| DrugBank Pharmacology: | Setiptiline is a tertacyclic antidepressant . It acts to reduce the symptoms of major depressive disorder. |
| DrugBank MoA: | Setiptiline is an antagonist at the α2 adrenergic receptor and at serotonin receptors . The antagonism of the α2 receptors likely relieves presynaptic inhibition of adrenergic neurotransmission, allowing for greater and longer sustained release of noradrenaline into the synapse. The antagonism of serotonin receptors may produce an upregulation of the receptors leading to an eventual increase in serotonergic signalling. The actual physiological mechanisms behind the antidepressant effect of setiptiline is unknown but the listed possibilities exist as likely explanations. |
| Targets: | Alpha-2 adrenergic receptors antagonist; Serotonin Receptors antagonist |
| Inclusion Criteria: | Indication associated |
